Results 171 to 180 of about 185,231 (352)

Extending Reperfusion Therapy for Acute Ischemic Stroke [PDF]

open access: bronze, 2005
Carlos A. Molina, Jeffrey L. Saver
openalex   +1 more source

Cell‐Free DNA‐Based Theranostics for Inflammatory Disorders

open access: yesAdvanced Science, EarlyView.
Summary on the dual potential of cfDNA as biomarkers and therapeutic targets for inflammatory disorders. Figure was created with BioRender.com. ABSTRACT Inflammatory disorders are characterized by immune‐mediated inflammatory cascades that can affect multiple organs.
Jiatong Li   +7 more
wiley   +1 more source

Acute stroke imaging research roadmap [PDF]

open access: yes, 2008
Albers, G.W.   +21 more
core   +1 more source

Defining reperfusion post endovascular therapy in ischemic stroke using MR-dynamic contrast enhanced perfusion [PDF]

open access: bronze, 2020
Christopher D. d’Esterre   +9 more
openalex   +1 more source

Migrasomes in Ischemic Stroke: Molecular Landscape and Pathophysiological Impact

open access: yesAdvanced Science, EarlyView.
Multi‐omics profiling of stroke patients exposes systemic molecular fingerprints of immune activation, oxidative stress and metabolic collapse. Complement and coagulation cascade, and cholesterol metabolism emerge as shared functional hallmarks of plasma migrasomes in stroke patients and migrasomes isolated from experimental stroke mice.
Huifen Zhou   +16 more
wiley   +1 more source

Remote Activation of Spinal TRPV1 by Magnetic Nanocubes Confers Cardioprotection Against Myocardial Ischemia‐Reperfusion Injury

open access: yesAdvanced Science, EarlyView.
Fe‐based magnetic nanocubes conjugated with TRPV1 antibodies (FeNCs‐TRPV1) are developed for the specific targeting of TRPV1 channels. Intraspinally injected FeNCs‐TRPV1 induces TRPV1 desensitization in rats exposed to repetitive and transient ACMF.
Xueying Cheng   +15 more
wiley   +1 more source

Coagulation disorders after reperfusion of pancreatic allografts [PDF]

open access: yes, 1993
Blumenstock, I.   +5 more
core   +1 more source

TRIM40 Drives Pathological Cardiac Hypertrophy and Heart Failure via Ubiquitination of PKN2

open access: yesAdvanced Science, EarlyView.
This study identifies the E3 ligase TRIM40 as a key driver of pathological cardiac hypertrophy. TRIM40 binds PKN2 via its B‐box domain and, through its C29‐dependent catalytic activity, mediates K63‐linked ubiquitination of PKN2. This modification enhances PKN2 phosphorylation at Ser815, thereby driving hypertrophy.
Risheng Zhao   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy